Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Cindy P. Garris
Observed names:
C GARRIS,
C Garris,
C. Garris,
C.P. Garris,
Cindy Garris,
Cindy P Garris
show all 6
Institution:
ViiV Healthcare (United Kingdom)
Observed institutions:
Kaiser Permanente,
GlaxoSmithKline (United Kingdom),
Kaiser Permanente San Diego Medical Center,
ViiV Healthcare (United Kingdom),
GlaxoSmithKline (United States)
ORCID:
0000-0002-2685-1204
Observed ORCID:
0000-0002-2685-1204
OpenAlex ID:
A5028839724
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients
2004
·
Joseph C Gathe
, Prudence Ive
, et al.
·
AIDS
·
209
Asthma That Is Not Well-Controlled Is Associated with Increased Healthcare Utilization and Decreased Quality of Life
2010
·
Theresa W. Guilbert
, Cindy Garris
, et al.
·
Journal of Asthma
·
163
Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan
2013
·
Cindy Garris
, Priti Jhingran
, et al.
·
Journal of Medical Economics
·
121
PDF
Reliability, validity, and responsiveness of the Rhinitis Control Assessment Test in patients with rhinitis
2012
·
Eli O. Meltzer
, Michael Schatz
, et al.
·
Journal of Allergy and Clinical Immunology
·
121
PDF
Development and Validation of the Lupus Impact Tracker: A Patient‐Completed Tool for Clinical Practice to Assess and Monitor the Impact of Systemic Lupus Erythematosus
2014
·
Meenakshi Jolly
, Cindy P. Garris
, et al.
·
Arthritis Care & Research
·
68
Perspectives of people living with HIV‐1 on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation‐effectiveness study
2022
·
Cindy P. Garris
, Maggie Czarnogorski
, et al.
·
Journal of the International AIDS Society
·
54
PDF
Impact of systemic lupus erythematosus on burden of illness and work productivity in the United States
2013
·
C Garris
, A Oglesby
, et al.
·
Lupus
·
46
Perspectives of healthcare providers on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation‐effectiveness study (CUSTOMIZE)
2022
·
Maggie Czarnogorski
, Cindy P. Garris
, et al.
·
Journal of the International AIDS Society
·
44
PDF
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
2021
·
Anthony Mills
, Gary J. Richmond
, et al.
·
AIDS
·
41
The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
2015
·
Cindy Garris
, Manan Shah
, et al.
·
Cost Effectiveness and Resource Allocation
·
40
PDF
Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options
2020
·
Kristina L. Bajema
, Robin M. Nance
, et al.
·
AIDS
·
38
Prospective Validation of the Lupus Impact Tracker: A Patient‐Completed Tool for Clinical Practice to Evaluate the Impact of Systemic Lupus Erythematosus
2016
·
Meenakshi Jolly
, Mark Kosinski
, et al.
·
Arthritis & Rheumatology
·
38
“I feel empowered”: women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain
2020
·
Andrea Mantsios
, Miranda Murray
, et al.
·
Culture Health & Sexuality
·
32
Fluticasone furoate nasal spray reduces symptoms of uncomplicated acute rhinosinusitis: a randomised placebo-controlled study
2012
·
Paul K Keith
, Andrzej Dymek
, et al.
·
Primary Care Respiratory Journal
·
29
PDF
Long-Term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: An uncontrolled, open-label, single-arm follow-on study
2006
·
Joseph C. Gathe
, Robin Wood
, et al.
·
Clinical Therapeutics
·
29
Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration
2024
·
Paula Teichner
, Nadine Chamay
, et al.
·
Open Forum Infectious Diseases
·
27
Patient and Physician Preferences for Regimen Attributes for the Treatment of HIV in the United States and Canada
2022
·
Heather Gelhorn
, Cindy Garris
, et al.
·
Journal of Personalized Medicine
·
21
PDF
Clinical Outcomes and Perspectives of People With Human Immunodeficiency Virus Type 1 Twelve Months After Initiation of Long-acting Cabotegravir and Rilpivirine in an Observational Real-world US Study (BEYOND)
2025
·
Dima Dandachi
, Cindy Garris
, et al.
·
Open Forum Infectious Diseases
·
18
PDF
Comparison of patient preference for sensory attributes of fluticasone furoate or fluticasone propionate in adults with seasonal allergic rhinitis: a randomized, placebo-controlled, double-blind study
2010
·
Eli O. Meltzer
, Charles Andrews
, et al.
·
Annals of Allergy Asthma & Immunology
·
17
Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment among People Living with HIV
2020
·
Louis S. Matza
, Trena M. Paulus
, et al.
·
Patient
·
16
PDF
Evaluation of Sex Differences of Fosamprenavir (With and Without Ritonavir) in HIV-Infected Men and Women
2007
·
Risa M. Hoffman
, Obiamiwe C. Umeh
, et al.
·
HIV Clinical Trials
·
16
PDF
Comparison of Corticosteroid Nasal Sprays in Relation to Concomitant Use and Cost of Other Prescription Medications to Treat Allergic Rhinitis Symptoms: Retrospective Cohort Analysis of Pharmacy Claims Data
2009
·
Cindy Garris
, Manan Shah
, et al.
·
Clinical Drug Investigation
·
15
A Comparison of the Psychometric Properties of the Mini–Rhinitis Quality of Life Questionnaire and the Rhinitis Control Assessment Test
2012
·
Michael Schatz
, Robert S. Zeiger
, et al.
·
American Journal of Rhinology and Allergy
·
13
Retrospective analysis of adherence to HIV treatment and healthcare utilization in a commercially insured population
2021
·
Julie Priest
, Rachel H. Bhak
, et al.
·
Journal of Medical Economics
·
11
PDF
Safety profile and tolerability of amprenavir in patients enrolled in an early access program
2001
·
Trevor Scott
, Cindy Garris
, et al.
·
Clinical Therapeutics
·
10
Show more works
View as search
Works count:
62
Citation count:
1,320
H-index:
18
I10-index:
25
Year
Topic
Type